Annals of Coloproctology

  • 제34권6호
  • /
  • Pages.312-316
  • /
  • 2018
  • /
  • 2287-9714(pISSN)
  • /
  • 2287-9722(eISSN)
대한대장항문학회 (The Korean Society of Coloproctology)
권호 표지
DOI QR코드

DOI QR Code

Chemotherapeutic Response and Survival for Patients With an Anal Squamous Cell Carcinoma and Low Hemoglobin Levels

  • Naqvi, A. (Colorectal Unit, Derriford Hospital, Plymouth Hospital NHS Trust) ;
  • Platt, E. (Colorectal Unit, Derriford Hospital, Plymouth Hospital NHS Trust) ;
  • Jitsumura, M. (Colorectal Unit, Singleton Hospital, Abertawe Bro Morgannwg University Health Board) ;
  • Evans, M. (Colorectal Unit, Singleton Hospital, Abertawe Bro Morgannwg University Health Board) ;
  • Coleman, M. (Colorectal Unit, Derriford Hospital, Plymouth Hospital NHS Trust) ;
  • Smolarek, S. (Colorectal Unit, Derriford Hospital, Plymouth Hospital NHS Trust)
  • 투고 : 2017.07.07
  • 심사 : 2017.10.12
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Anemia is associated with poor treatment results for a variety of cancers. The effect of low hemoglobin levels on long-term outcomes after the treatment of patients with an anal squamous cell carcinoma (SCC) remains unclear. For that reason, this study aimed to investigate the effect of anemia on treatment outcomes following chemoradiation for an anal SCC. Methods: This was a retrospective study of all patients who underwent curative treatment for an anal SCC between 2009 and 2015 at 2 trusts in the United Kingdom. Data were collated from prospectively collected cancer databases and were cross-checked with operating-room records and records in the hospitals' patient management systems. Results: We identified 103 patients with a median age of 63 years (range, 36-84 years). The median overall survival was 39 months (range, 9-90 months), and the disease-free survival was 36 months (range, 2-90 months). During the follow-up period, 16.5% patients died and 13.6% patients developed recurrence. Twenty-two people were anemic prior to treatment, with a female preponderance (20 of 22). No differences in disease-free survival (P = 0.74) and overall survival (P = 0.12) were noted between patients with anemia and those with normal hemoglobin levels. On regression the analysis, the combination of anemia, the presence of a defunctioning colostomy, lymph-node involvement and higher tumor stage correlated with poor overall survival. Conclusion: In this study, anemia did not influence disease-free survival or overall survival. We suggest that the interaction between anemia and survival is more complex than previously demonstrated and potentially reliant on other coexisting factors.

키워드

참고문헌

  1. Cancer Research UK. Anal cancer statistics [Internet]. London: Cancer Research UK; [cited 2017 Jul 3]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/anal-cancer.
  2. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354-6. https://doi.org/10.1007/BF02586980
  3. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508. https://doi.org/10.1634/theoncologist.7-6-492
  4. Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, et al. Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol 2007; 86:37-41. https://doi.org/10.1532/IJH97.07040
  5. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006;70:34-48. https://doi.org/10.1159/000091675
  6. American Joint Committee on Cancer. Implementation of AJCC 8th Edition Cancer Staging System [Internet]. Chicago (IL): American Joint Committee on Cancer; c2018 [cited 2017 Jul 3]. Available from: https://cancerstaging.org/About/news/Pages/Implementation-of-AJCC-8th-Edition-Cancer-Staging-System.aspx.
  7. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21. https://doi.org/10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P
  8. Oblak I, Cesnjevar M, Anzic M, Hadzic JB, Ermenc AS, Anderluh F, et al. The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin. Radiol Oncol 2016;50:113-20.
  9. Banerjee R, Roxin G, Eliasziw M, Joseph K, Maclean A, Buie WD, et al. The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy. Dis Colon Rectum 2013;56:1036-42. https://doi.org/10.1097/DCR.0b013e31829ab0d4
  10. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306. https://doi.org/10.1016/j.ejca.2004.06.019
  11. Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol Hemoter 2016;38:325-30.
  12. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-82. https://doi.org/10.1093/annonc/mds338
  13. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev 2016;2:CD009624.